Abstract
Overview
Introduction
This analysis examines the historical and forecast performance for Merck-Serono in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.
Key reasons to read this report
Benchmark Merck-Serono' s performance against key rivals in the ethical pharmaceutical sector
Learn how, led by Rebif and Erbitux, Merck-Serono is set to record strong growth relative to its peer set in the period to 2012
Evaluate the prospects of Merck-Serono' s late-stage pipeline, which is heavily dependent on the oral MS drug Mylinax
View Cart
